Xencor, Inc.

Equities

XNCR

US98401F1057

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
19.98 ^USD	+3.90%		+8.71%	-5.89%

Apr. 16	BTIG Cuts Price Target on Xencor to $38 From $56, Keeps Buy Rating	MT
Apr. 09	Xencor Names Bart Cornelissen as Chief Financial Officer	MT

John J. Kuch to Retire as Chief Financial Officer of Xencor, Inc. in March 2024

October 26, 2023 at 08:01 am EDT

Xencor, Inc. announced that John J. Kuch, chief financial officer, plans to retire in March 2024, after a 23-year career with Xencor and over 40 years in corporate finance. Mr. Kuch will support the search for a new chief financial officer and has agreed to enter into a consulting agreement following a transition period.

Latest news about Xencor, Inc.

BTIG Cuts Price Target on Xencor to $38 From $56, Keeps Buy Rating	Apr. 16	MT
Xencor Names Bart Cornelissen as Chief Financial Officer	Apr. 09	MT
Xencor, Inc. Announces CFO Changes	Apr. 09	CI
Xencor Appoints Bart Cornelissen as Senior Vice President	Apr. 09	CI
Transcript : Xencor, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 11:15 AM	Mar. 14
Xencor Insider Sold Shares Worth $293,519, According to a Recent SEC Filing	Mar. 07	MT
North American Morning Briefing : Fed's Preferred -2-	Feb. 29	DJ
Wedbush Adjusts Xencor's Price Target to $34 From $36, Keeps Outperform Rating	Feb. 28	MT
Transcript : Xencor, Inc., Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
Earnings Flash (XNCR) XENCOR Posts Q4 Revenue $44.7M, vs. Street Est of $74.7M	Feb. 27	MT
Xencor, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
Xencor Insider Sold Shares Worth $1,048,743, According to a Recent SEC Filing	Feb. 14	MT
Transcript : Xencor, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM	Jan. 10
Xencor, Inc. Appoints Dane Leone as Senior Vice President, Corporate Strategy	Jan. 02	CI
Xencor Insider Sold Shares Worth $941,670, According to a Recent SEC Filing	Dec. 29	MT
Xencor, Inc. Enters into an Amended and Restated Collaboration and License Agreement with Genentech, Inc	Nov. 15	CI
RBC Cuts Price Target on Xencor to $32 From $36, Keeps Outperform, Speculative Risk	Nov. 08	MT
Wedbush Trims Xencor's PT to $36 From $37 After Stopping XmAb104 Development, Opting Out of Cost Sharing With Genentech to Co-develop XmAb306; Maintains Outperform Rating	Nov. 08	MT
Transcript : Xencor, Inc., Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07
Earnings Flash (XNCR) XENCOR Reports Q3 Revenue $59.2M, vs. Street Est of $30M	Nov. 07	MT
Xencor, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Xencor, Inc. and OCM Life Sciences Portfolio LP, Entere into A Royalty Purchase Agreement	Nov. 07	CI
Xencor Says Cancer Drug Candidates Showed Anti-Tumor Activity in Preclinical Trials	Nov. 03	MT
Xencor Says CFO John Kuch to Retire in March	23-10-26	MT
John J. Kuch to Retire as Chief Financial Officer of Xencor, Inc. in March 2024	23-10-26	CI

Chart Xencor, Inc.

Duration

Period

More charts

Company Profile

Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Xencor, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

19.98 USD

Average target price

36.18 USD

Spread / Average Target

+81.09%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
XENCOR, INC.	-5.89%	1.23B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs